Feb. 20, 2026: SynDevRx today announced the publication of a seminal research article in Frontiers in Oncology detailing the anti-tumor and systemic metabolic improvements of its lead investigational therapy, evexomostat in pre-clinical models of obesity-accelerated cancer.
